|

Olaparib + Elacestrant Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • GBG Forschungs GmbH1

Indications

  • Advanced or Metastatic Breast Cancer1
  • Hormone Receptor Positive HER-2 Negative Breast Cancer1
  • BRCA2 Mutation1
  • BRCA1 Mutation1
  • Breast Cancer1

Other1 trial

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.